Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Issues
2022
November 2022, Vol 12, No 11
November 2022, Vol 12, No 11
Preservation of Liver Function in Patients with Metastatic iCCA with Extrahepatic Disease
Cholangiocarcinoma
A single-institution experience in treating patients with metastatic iCCA with local liver-directed radiation therapy (RT) was presented by Rituraj Upadhyay, MD, at the 2022 American Society of Clinical Oncology Annual Meeting.
Read More ›
Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion
FDA Approvals, News & Updates
On September 30, 2022, the FDA accelerated the approval of futibatinib (Lytgobi; Taiho Oncology), a tyrosine kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (CCA) and
FGFR2
gene fusion or other rearrangements.
Read More ›
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Malignancies
FDA Approvals, News & Updates
On September 28, 2022, the FDA approved bevacizumab-adcd (Vegzelma; Celltrion), a VEGF inhibitor and a biosimilar to bevacizumab (Avastin), for the treatment of metastatic colorectal cancer; recurrent or metastatic non-squamous non–small-cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal-cell carcinoma; persistent, recurrent, or metastatic cervical cancer; and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Read More ›
Pedmark First Drug Approved for Hearing Loss Prevention in Children with Solid Tumors
FDA Approvals, News & Updates
On September 20, 2022, the FDA approved sodium thiosulfate (Pedmark; Fennec Pharmaceuticals), an inorganic sodium salt, for risk reduction of hearing loss (ototoxicity) associated with cisplatin treatment in children aged ≥1 month to 18 years with nonmetastatic solid tumors.
Read More ›
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
FDA Approvals, News & Updates
On
September 21, 2022
, the FDA accelerated the approval of selpercatinib (Retevmo; Eli Lilly), a selective
RET
kinase inhibitor, for the treatment of all locally advanced or metastatic solid tumors with a
RET
gene fusion in patients whose disease progressed during or after systemic treatment or who have no alternative treatment options.
Read More ›
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
FDA Approvals, News & Updates
On
September 2, 2022
, the FDA accelerated the approval of durvalumab (Imfinzi; AstraZeneca), a PD-L1 inhibitor, in combination with gemcitabine and cisplatin, for adults with locally advanced or metastatic biliary tract cancer.
Read More ›
Pemazyre Receives New Indication for FGFR1-Positive Myeloid/Lymphoid Neoplasms
FDA Approvals, News & Updates
On
August 26, 2022
, the FDA accelerated the approval of pemigatinib (Pemazyre; Incyte), a tyrosine kinase inhibitor, for the treatment of relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with
FGFR1
rearrangements in adults. Pemigatinib received a breakthrough therapy designation for this indication.
Read More ›
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
FDA Approvals, News & Updates
On
August 24, 2022
, the FDA accelerated the approval of ibrutinib (Imbruvica; Pharmacyclics), a Bruton tyrosine kinase inhibitor, for chronic graft-versus-host disease (GVHD) in pediatric patients aged ≥1 year whose disease did not respond to ≥1 lines of systemic therapy. Concomitantly, the FDA approved a new oral suspension formulation of ibrutinib for use in this patient population.
Read More ›
Page 2 of 2
1
2
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Outs: What Are the Implications for Patients and Practices?
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
New Policies Regarding Intravenous Iron Replacement Are Creating Conundrum for Providers and Payers
By
Dawn Holcombe, MBA, FACMPE, ACHE
3.
2023 Spotlight: Amgen
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes